Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 5/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | SCN1A | P35498 | 2/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.48 |
| ▸ | CCR1 | P32246 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | CCR3 | P51677 | 2/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502923 | 0.92 | CYP2D6 (0.52) | CYP2D6DRD4DRD2DRD3SCN1A | |
| SCHEMBL27587187 | 0.89 | HRH1 (0.52) | CYP2D6DRD4DRD2DRD3SCN1A | |
| SCHEMBL6210324 | 0.86 | CYP2D6 (0.55) | CYP2D6DRD4DRD2DRD3SCN1A | |
| SCHEMBL6214634 | 0.86 | ABCB1 (0.59) | DRD4DRD2DRD3CCR1HRH1 | |
| SCHEMBL6075131 | 0.86 | DRD4 (0.51) | DRD4DRD2DRD3SCN1ASCN5A | |
| SCHEMBL27587199 | 0.84 | CYP2D6 (0.53) | CYP2D6DRD4SCN1ASCN5ASCN9A | |
| SCHEMBL6210369 | 0.84 | ABCB1 (0.60) | DRD4DRD2DRD3ABCB1KCNH2 | |
| SCHEMBL6216008 | 0.84 | ABCB1 (0.47) | CYP2D6DRD4DRD2DRD3SCN1A | |
| SCHEMBL27568028 | 0.84 | DRD2 (0.50) | CYP2D6DRD4DRD2DRD3SCN1A | |
| SCHEMBL6212528 | 0.84 | CYP2D6 (0.47) | CYP2D6DRD4DRD2DRD3SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263724-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | EP | claimed |
| US-20030149047-A1 | Novel compounds | ASTRAZENCA AB (SE) | 2003-08-07 | — | — | US | claimed |
| EP-1263724-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | claimed |
| WO-2001062728-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | claimed |
| US-6943188-B2 | Hydroxyalkyl compounds | ASTRAZENECA AB (SE) | 2005-09-13 | — | — | US | disclosed |
| US-6927222-B2 | 1,3,4,5-tetrahydro-pyrido(4,3-b)indole-2-yl derivative useful for treating rheumatoid arthritis, chronic obstructive pulmonary disease, asthma and multple sclerosis | ASTRAZENECA AB (SE) | 2005-08-09 | — | — | US | disclosed |
| EP-1263724-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | EP | disclosed |
| US-20030158225-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | US | disclosed |
| US-20030149047-A1 | Novel compounds | ASTRAZENCA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| US-20030144267-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
| EP-1263760-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| EP-1263725-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| EP-1263724-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001062757-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062728-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062729-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158225-A1 | Novel compounds | UGT2B7, RPS4Y1, RPS4X | CYP2D6 7/4885DRD4 519/4885DRD2 840/4885 |
| US-20030149047-A1 | Novel compounds | RPS4Y1, RPS4X, RPS6 | CYP2D6 8/4885DRD4 433/4885DRD2 879/4885 |
| US-20030144267-A1 | Novel compounds | RPS4X, RPS4Y1, UGT2B7 | CYP2D6 7/4885DRD4 426/4885DRD2 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.